LGT Capital Partners LTD. Sells 69,557 Shares of Stryker Co. (NYSE:SYK)

LGT Capital Partners LTD. reduced its stake in shares of Stryker Co. (NYSE:SYK) by 24.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,133 shares of the medical technology company’s stock after selling 69,557 shares during the quarter. Stryker accounts for approximately 2.9% of LGT Capital Partners LTD.’s portfolio, making the stock its 13th largest holding. LGT Capital Partners LTD. owned about 0.06% of Stryker worth $76,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker in the fourth quarter worth about $25,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the fourth quarter worth about $30,000. BankPlus Trust Department bought a new stake in shares of Stryker in the fourth quarter worth about $33,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Stryker in the third quarter worth about $36,000. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $379.28 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $144.73 billion, a P/E ratio of 48.88, a PEG ratio of 2.93 and a beta of 0.95. The company has a 50 day moving average of $382.45 and a 200 day moving average of $372.99. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

Several research firms recently issued reports on SYK. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Canaccord Genuity Group raised their target price on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Stifel Nicolaus raised their target price on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Argus set a $450.00 price objective on shares of Stryker in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.